ClinicalTrials.gov
public full text
Public Domain
Docetaxel in Treating Patients With Refractory or Recurrent Advanced Gynecologic Cancer
RATIONALE: Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Docetaxel may also stop the growth of tumor cells by blocking blood flow to the tumor. Giving daily doses of docetaxel may kill more tumor cells. PURPOSE: This phase I trial is studying the side effects and best dose of docetaxel in treating patients with refractory or recurrent advanced gynecologic cancer.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Lenalidomide and Docetaxel in Treating Patients With Advanced Solid Tumors#1170607
- Docetaxel and Carboplatin in Treating Patients With Ovarian Epithelial, Fallopian Tube, or Peritoneal Cavity Cancer#834441
- Neoadjuvant Docetaxel in Treating Women With Newly Diagnosed Breast Cancer#967860
- Chemotherapy in Treating Women With Breast Cancer That Can Be Surgically Removed#1172122
- Tariquidar and Docetaxel to Treat Patients With Lung, Ovarian, Renal and Cervical Cancer#208474
Record · ID 1033351
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive